Trademark: 88814224
Word
TAKING CANCER PERSONALLY
Status
Dead
Status Code
606
Status Date
Monday, November 7, 2022
Serial Number
88814224
Mark Type
4000
Filing Date
Friday, February 28, 2020
Published for Opposition
Tuesday, February 9, 2021
Abandoned Date
Monday, November 7, 2022

Trademark Owner History
NeoGenomics Laboratories, Inc. - Owner At Publication

Classifications
41 Providing online non-downloadable reports to others in the fields of pathology, medical diagnostic testing and oncology testing; education services, namely, providing training and on-demand on-line training in the form of courses, seminars and workshops in the fields of health, health related topics, cancer, cancer pathology, pathology, scientific testing and research services, medical testing, medical tests, diagnostic testing, oncology testing, human disease and human medical conditions; education services, namely, providing non-downloadable webinars in the fields of health, health related topics, cancer, cancer pathology, pathology, scientific testing and research services, medical testing, medical tests, diagnostic testing, oncology testing, human disease and human medical conditions; providing online, non-downloadable reports for others in the fields of medical tests, medical testing, medical research, pathology, diagnostic testing, oncology testing and human disease and medical conditions
5 Medical tests kits primarily comprised of medical diagnostic reagents and assays for testing body fluids
16 Printed medical reports in the field of cancer research; printed publications, namely, newsletters and abstracts in the fields of pathology, medical testing, medical tests, diagnostic testing, oncology testing, human disease and human medical conditions; printed reports for others in the fields of pathology, medical diagnostic testing and oncology testing
1 Pre-packaged medical tests kits and medical test kits to aid in the diagnosis of disease or cancer, namely, kits primarily composed of DNA probes being biochemical reagents used for detecting and analyzing molecules in protein or nucleotide arrays and also containing clinical medical reagents and antibodies for use in disease testing for clinical medical laboratory use
42 Medical research; genetic mapping for scientific purposes, namely, gene sequencing; genetic testing and sequencing for scientific purposes; molecular sequencing for scientific purposes; cancer study and analysis, cytometry, cytogenetics, cell analysis, cell preservation, clinical study and testing of cells, all being for scientific and/or research purposes; clinical study and testing of cells all being for scientific purposes; medical and scientific research information in the field of gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells for scientific or research purposes; medical and scientific research in the field of gene sequencing, molecular sequencing, cancer study and analysis, cytometry, cytogenetics, cell analysis, cell preservation, clinical study and testing of cells, and cancer; providing scientific and/or research information to others in the fields of oncology, pathology and gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells scientific testing and research services and clinical scientific testing; providing an internet website portal featuring gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells all for scientific and/or research purposes; scientific and medical research information in the fields of scientific testing and research services, medical research services, and clinical scientific testing; providing cloud-based scientific and medical research information in the nature of providing temporary use of nondownloadable cloud based software for providing information to others in the field of scientific testing and research services, medical research services, and clinical scientific testing; providing temporary use of online non-downloadable software for analysis of medical test results; temporary use of online non-downloadable software for enhancement of analysis, research, and review of information pertaining to medical, scientific, genetic, testing and analysis, and information and pertaining to such testing and analysis; software as a service (SAAS) services featuring software for analysis of medical test results; non-downloadable computer software for enhancement of analysis, research, and review of information pertaining to medical, scientific, genetic, testing and analysis, and information pertaining to testing and analysis; providing medical research and scientific research information in the field of oncology; scientific testing and research services in the field of human disease and human medical conditions; providing medical research services in the field of human disease and human medical conditions; providing clinical scientific testing services and medical research and testing for scientific purposes in the field of human disease and human medical conditions; clinical laboratory research services, oncology reference laboratory services for research or scientific purposes, providing medical research information and interactive information to others in the fields of medical tests, medical testing, medical research, pathology, diagnostic testing, oncology testing and human disease and medical conditions; providing cloud-based information in the nature of providing temporary use of nondownloadable cloud based software for providing information to others in the field of scientific testing and research, medical research, and clinical scientific testing; providing online non-downloadable Internet-based software for medical testing and analysis of medical test results; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; medical and scientific research, namely, conducting clinical trials for others; conducting research and clinical trials for others relating to medical devices and pharmaceuticals

Trademark Events
Nov 7, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Nov 7, 2022
Abandonment - No Use Statement Filed
Jun 13, 2022
Teas Change Of Correspondence Received
Jun 13, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 13, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 7, 2022
Notice Of Approval Of Extension Request E-Mailed
Apr 6, 2022
Sou Extension 2 Granted
Apr 4, 2022
Sou Extension 2 Filed
Apr 4, 2022
Sou Teas Extension Received
Oct 8, 2021
Notice Of Approval Of Extension Request E-Mailed
Oct 7, 2021
Sou Extension 1 Granted
Oct 4, 2021
Sou Extension 1 Filed
Oct 7, 2021
Case Assigned To Intent To Use Paralegal
Oct 4, 2021
Sou Teas Extension Received
Oct 4, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 4, 2021
Teas Change Of Correspondence Received
Oct 4, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 4, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 4, 2021
Teas Change Of Owner Address Received
Apr 6, 2021
Noa E-Mailed - Sou Required From Applicant
Feb 9, 2021
Official Gazette Publication Confirmation E-Mailed
Feb 9, 2021
Published For Opposition
Jan 20, 2021
Notification Of Notice Of Publication E-Mailed
Jan 6, 2021
Approved For Pub - Principal Register
Dec 30, 2020
Teas/Email Correspondence Entered
Dec 30, 2020
Correspondence Received In Law Office
Dec 28, 2020
Teas Response To Office Action Received
Dec 7, 2020
Notification Of Non-Final Action E-Mailed
Dec 7, 2020
Non-Final Action E-Mailed
Dec 7, 2020
Non-Final Action Written
Dec 7, 2020
Notification Of Final Refusal Emailed
Dec 7, 2020
Final Refusal E-Mailed
Dec 7, 2020
Final Refusal Written
Nov 16, 2020
Teas/Email Correspondence Entered
Nov 16, 2020
Correspondence Received In Law Office
Nov 16, 2020
Assigned To Lie
Oct 14, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 14, 2020
Teas Change Of Correspondence Received
Oct 14, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 14, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 14, 2020
Teas Change Of Owner Address Received
Oct 14, 2020
Teas Response To Office Action Received
Apr 26, 2020
Notification Of Priority Action E-Mailed
Apr 26, 2020
Priority Action E-Mailed
Apr 26, 2020
Priority Action Written
Apr 17, 2020
Assigned To Examiner
Mar 5, 2020
New Application Office Supplied Data Entered
Mar 5, 2020
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24